Renaissance Technologies LLC reduced its position in bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) by 73.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 757,110 shares of the biotechnology company’s stock after selling 2,052,890 shares during the period. Renaissance Technologies LLC’s holdings in bluebird bio were worth $4,793,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Verition Fund Management LLC purchased a new position in bluebird bio during the third quarter valued at $233,000. Boothbay Fund Management LLC purchased a new position in bluebird bio during the third quarter valued at $518,000. Nuveen Asset Management LLC lifted its position in bluebird bio by 244.6% during the third quarter. Nuveen Asset Management LLC now owns 1,120,044 shares of the biotechnology company’s stock valued at $7,090,000 after purchasing an additional 794,995 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its position in bluebird bio by 142.4% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 2,744 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in bluebird bio during the third quarter valued at $422,000. 79.01% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at bluebird bio
In other bluebird bio news, Director Nick Leschly sold 4,290 shares of the firm’s stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total transaction of $33,462.00. Following the sale, the director now directly owns 280,149 shares of the company’s stock, valued at $2,185,162.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 8,025 shares of company stock valued at $62,595 over the last ninety days. 2.90% of the stock is currently owned by company insiders.
bluebird bio Stock Down 15.9 %
Wall Street Analyst Weigh In
Several research firms recently weighed in on BLUE. Robert W. Baird began coverage on bluebird bio in a research report on Monday, March 6th. They set an “outperform” rating and a $10.00 target price on the stock. Morgan Stanley lifted their target price on bluebird bio from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Tuesday, January 24th. Finally, SVB Leerink lowered their target price on bluebird bio from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Monday, January 23rd. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.00.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE – Get Rating).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.